Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia

Next Previous
Search
Trial Profile

A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pilocarpine (Primary)
  • Indications Presbyopia
  • Focus Therapeutic Use
  • Sponsors Orasis Pharmaceuticals

    • Most Recent Events

    • 12 Apr 2022 According to a media release, the company will present the data from this study at the 2022 American Society for Cataract and Refractive Surgery (ASCRS) Annual Meeting, by the Marjan Farid, M.D. and Preeya K. Gupta, M.D..
    • 09 Oct 2019 Status changed from recruiting to completed.
    • 28 Mar 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top